Pyxis Oncology Inc (PYXS)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$1.89-4.55%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put PYXS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 4% on a typical day and fell roughly 57% in its worst 12-month stretch.
View RiskPYXS’s case rests on advancing MICVO’s clinical development, supported by financing extending cash runway into Q2 2027. The latest quarter missed GAAP EPS consensus by 17.6%, and the company reported a $25.35 million net loss. The price reflects less growth than our forecast, but no clean valuation multiple is available. A next-quarter miss probability of 54% puts execution at risk. The public offering may dilute shares, creating another risk to the runway case. Peer multiples imply a price about 76% above where it trades (it looks cheap on this basis). Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-29. PYXS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering PYXS (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for PYXS in the last 4 months.
Continue this research
Compare PYXS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PYXS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put PYXS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance MICVO clinical development and report key data updates
Better runway supports MICVO clinical development efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $1.89
The last 12 months of price, then the range of analyst 12-month targets from today’s $1.89.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Extend cash runway into Q2 2027 via private placement financing
Financing extends cash runway into Q2 2027.
Threatens: Extend cash runway into Q2 2027 via private placement financing
Public offering may dilute shares and impact cash runway.
Threatens: Extend cash runway into Q2 2027 via private placement financing
Public offering may dilute shares and affect cash runway.
Threatens: Advance MICVO clinical development and report key data updates
Setbacks delay MICVO clinical development timeline significantly.
Advances: Advance MICVO clinical development and report key data updates
Wells Fargo's target raise indicates confidence in MICVO data.
